BBNX

Beta Bionics, Inc. (BBNX) Business Model Analysis (2026)

Invetso Score: 5/10 — Balanced · Last Updated: 2026-08-01

Overall Score

Revenue Model

The company appears to generate revenue with a gross margin of 58.3% and revenue per share of 2.67.

Valuation remains elevated at 6.32x EV/Sales, suggesting investors are still paying for growth or optionality despite weak profitability.

Profitability

TTM margins remain deeply negative, with EBIT margin at -63.1%, EBITDA margin at -60.3%, and net profit margin at -61.3%.

Returns on capital are also negative, including ROIC at -31.0% and ROE at -26.3%, indicating the business is not yet producing economic profits.

Financial Strength

Liquidity is very strong, with a current ratio of 8.88x and quick ratio of 7.96x.

Leverage is low, with debt-to-equity at 0.03x and debt-to-assets at 0.02x, giving the company substantial balance-sheet flexibility.

Efficiency

Asset turnover is modest at 0.41x, while fixed asset turnover is stronger at 7.19x, indicating mixed operating efficiency.

Working capital remains positive at 205.0M, but the cash conversion cycle is long at 197.8 days due to 176.0 days of inventory outstanding.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Beta Bionics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →